WuXi AppTec Announces Change in Accounting Policy to Enhance Financial Reporting

An update from WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) is now available.

WuXi AppTec Co., Ltd. has announced a change in its accounting policy to better reflect its main business operations and growth drivers. The company’s reportable segments have been restructured to focus on WuXi Chemistry, WuXi Testing, WuXi Biology, and other non-core businesses, which is expected to streamline operations and provide more relevant financial reporting.

More about WuXi AppTec Co., Ltd. Class H

WuXi AppTec Co., Ltd. operates as a Contract Research Development and Manufacturing Organization (CRDMO) in the pharmaceutical industry. The company offers a range of services including chemical drug R&D and production, biology discovery, preclinical testing, and clinical research services, aiming to enhance R&D efficiency and deliver innovative treatments.

YTD Price Performance: 14.16%

Average Trading Volume: 5,403,051

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$194.8B

For an in-depth examination of 2359 stock, go to TipRanks’ Stock Analysis page.